Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

TYK2 inhibition may help treat alopecia areata by promoting hair growth and reducing immune response.

Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.

Ritlecitinib effectively treats alopecia areata in patients 12 and older with fewer side effects.

Combining pentoxifylline with corticosteroids improves alopecia areata treatment.

Dutasteride may help reduce brain inflammation and improve cognition.

Squaric acid dibutylester can cause severe skin reactions in people with allergies.

Tofacitinib helped most teenagers in the study regrow hair with mild side effects.

You might not need to stop cancer treatment if you get a rare skin reaction from EGFR inhibitors, as skin treatments can help manage it.

Two drugs, tofacitinib and ruxolitinib, may help regrow hair by activating hair follicles.

Brepocitinib effectively reduces inflammation and improves symptoms in cicatricial alopecia with good safety.

Standard dosing is more effective for severe alopecia areata in children, but unorthodox dosing can be safe and considered if needed.

Dupilumab helped a 13-year-old regrow hair after alopecia totalis.

A KLK5 inhibitor effectively improved skin symptoms in a mouse model of Netherton Syndrome.

Most patients improved in both atopic dermatitis and alopecia areata with certain treatments, but some had worsened symptoms, suggesting personalized care is needed.

Ruxolitinib treatment led to unexpected hair regrowth in a patient with alopecia universalis.

A humanized IL-2 fusion protein boosts T regulatory cells and helps control hair loss in Alopecia Areata.

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

Sex and race affect immune responses and treatment outcomes in Hidradenitis suppurativa.

Tofacitinib significantly improved skin and hair conditions without side effects.

Abrocitinib shows promise for treating various skin conditions beyond atopic dermatitis.

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

A man with vitiligo and alopecia saw quick skin and hair improvement with ruxolitinib, but skin color gains were lost after stopping treatment.

Upadacitinib effectively treated severe hair loss in a child.

Janus kinase inhibitors reduce inflammation markers in severe alopecia areata patients.

A woman had a severe skin reaction from the drug imiquimod, used for skin cancer, highlighting the need for awareness of rare but serious side effects.

Dupilumab can improve both atopic dermatitis and alopecia universalis.

JAK inhibitors may reduce depression in people with alopecia areata.

Brepocitinib reduces interferon signaling in hidradenitis suppurativa patients.

Ipilimumab can cause various adverse events in elderly patients, especially affecting the gastrointestinal and endocrine systems.